Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of AZD3366 in Healthy Subjects
NCT04588727Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2020
- Primary completion
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD3366 in cardiovascular disease (CVD) and myocardial infarction (MI) (4 arms), sponsored by AstraZeneca. Primary endpoint: Number of subjects with adverse events and serious adverse events. Started Oct 2020; status: completed.
02
Drugs
AZD3366
03
Conditions
cardiovascular disease (CVD)myocardial infarction (MI)
Beyond the preview
Go deeper on NCT04588727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04588727.